Evidence map›Paper›PMID 42103933›Full record

ArticleEMBO molecular medicine2026

Loss of mitochondrial DNA helicase in retinal macroglia drives neovascular retinopathy.

Sofiia Olander, Sinem Karaman, Fumi Suomi, Kevin Aguilar, Aleksandra Zhaivoron, Maiken Nedergaard, Lina Smeds, Jussi Tiihonen, Albert Quintana, Juan Hidalgo and 4 more

Abstract read
In one paragraph

Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sofiia OlanderStem Cells and Metabolism, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Sinem KaramanWihuri Research Institute and Translational Cancer Medicine Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-0719-1773
Fumi SuomiStem Cells and Metabolism, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-8883-3338
Kevin AguilarInstitute of Neurosciences, Universitat Autònoma de Barcelona, Bellaterra, Spain.ORCID 0000-0002-1452-2841
Aleksandra ZhaivoronStem Cells and Metabolism, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Maiken NedergaardCenter for Translational Neuromedicine, University of Copenhagen, Copenhagen, Denmark.
Lina SmedsMolecular and Integrative Biosciences Research Programme, University of Helsinki, Helsinki, Finland.
Jussi TiihonenMolecular and Integrative Biosciences Research Programme, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-0133-6126
Albert QuintanaInstitute of Neurosciences, Universitat Autònoma de Barcelona, Bellaterra, Spain.ORCID 0000-0003-1674-7160
Juan HidalgoInstitute of Neurosciences, Universitat Autònoma de Barcelona, Bellaterra, Spain.ORCID 0000-0003-0921-1122
Kari AlitaloWihuri Research Institute and Translational Cancer Medicine Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-7331-0902
Petri Ala-LaurilaMolecular and Integrative Biosciences Research Programme, University of Helsinki, Helsinki, Finland.
Gulayse Ince-DunnStem Cells and Metabolism, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland. gulayse.ince@gmail.com.ORCID 0000-0003-1352-990X
Anu SuomalainenStem Cells and Metabolism, Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland. anu.wartiovaara@helsinki.fi.ORCID 0000-0003-4833-5195

Funding

Academy of Finland - NIH joint call pilot (#345023Chan-Zuckerberg Initiative MET-0000000418European Research Council #743155ICREA Academia ID2020-114977RB-I00,RED2022-134786-Tla Caixa" Foundation LCF/PR/HR20/52400018Ministerio de Ciencia e Innovación y Fondo Europeo de Desarrollo Regional PID2021-126602OB-I00Next GenerationEU 2021SGR-720Research Council of Finland (AKA) #361873,#345248,#330053,#336126
6 · The paper itself

Abstract

Retinopathy is a common symptom in mitochondrial diseases, and a leading cause of blindness in working-age individuals, often arising as a consequence of diabetes. Here, we demonstrate that postnatal loss of the replicative helicase of mitochondrial DNA in the astrocytes and Müller glia induces neovascular retinopathy. In these retinas, the macroglia show pathological reactivation, leading to hallmark features of neovascularization with blood-retina-barrier leakage, secondary microgliosis, and complement cascade activation. Similar reactivation of astrocytes in the cerebral cortex does not compromise vascular integrity, indicating tissue-specific roles of mitochondrial metabolism in macroglia for vascular homeostasis. Three secreted angiogenic factors-Fgf2, Pgf, and Lcn2-known to contribute to diabetic retinopathy, were induced. Spike recordings of the most sensitive retinal ganglion cells revealed normal rod function and intact retinal coding. These findings highlight the critical role of glial mitochondrial metabolism in neovascular retinopathy, with important implications for therapy development for mitochondrial and common forms of vision loss.

Indexed as

DNA HelicasesEpendymoglial CellsNeurogliaRetinaRetinal NeovascularizationAnimalsAstrocytesDNA, MitochondrialHumansMiceMitochondriaDNA HelicasesDNA, Mitochondrial

Identifiers

PMID42103933
PMCPMC13365537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.